Insmed announces positive top-line results from phase 2 willow study of ins1007

Insmed announces positive top-line results from phase 2 willow study of ins1007 in patients with non-cystic fibrosis bronchiectasis.insmed inc - treatment with ins1007 also achieves key secondary endpoint of reduction of frequency of pulmonary exacerbation.insmed inc - ins1007 was generally well-tolerated at both dosage strengths.insmed inc - plans to advance ins1007 to phase 3 development.insmed - study achieves primary endpoint with statistically significant improvement.
INSM Ratings Summary
INSM Quant Ranking